1. [Use of sunitinib in metastatic renal cell carcinoma patients with poor prognosis].
- Author
-
Timofeev IV, Demidov LV, and Petenko NN
- Subjects
- Aged, Angiogenesis Inhibitors therapeutic use, Carcinoma, Renal Cell secondary, Disease-Free Survival, Female, Humans, Kidney Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, Sunitinib, Survival Analysis, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Renal Cell drug therapy, Indoles therapeutic use, Kidney Neoplasms drug therapy, Pyrroles therapeutic use
- Abstract
We evaluated overall and relapse-free survival in patients with metastatic renal cell carcinoma (MRCC) with poor prognosis. The study involved 92 patients (median age 54.1 years, male 63%, female 29%), retrospectively; 48.9% had poor prognosis. They received oral sunitinib 59 mg/day in 6 cycles (4 weeks on, 2 weeks off). Median overall survival was 17.6 months, relapse-free--10.8 months. Risk of progression in the poor and good prognosis groups was identical (HR=09). Overall response was 29% in poor prognosis and 40%--in good one (p = 0.07). Drug tolerability was acceptable in both groups. Sunitinib was effective in both groups of MRCC patients.
- Published
- 2011